Cardiff Oncology (CRDF) Net Equity Issued and Repurchased (2011 - 2024)

Cardiff Oncology has reported Net Equity Issued and Repurchased for 11 years, with the latest figure at $44.2 million in Q4 2024.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $44.2 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $51.6 million (changed N/A YoY) and the FY2024 annual result came in at $53.4 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased advanced to $44.2 million in Q4 2024 per CRDF's latest filing, from $7.4 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $94.0 million in Q4 2020 and troughed at -$523000.0 in Q3 2020.
• A 3-year average of $24.8 million and a median of $16.4 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 2021.68% in 2020, down 135.25% in 2020.
• Over 3 years, Net Equity Issued and Repurchased stood at $94.0 million in 2020, then tumbled by 84.09% to $15.0 million in 2021, then surged by 195.25% to $44.2 million in 2024.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $44.2 million, $7.4 million, and $15.0 million for Q4 2024, Q3 2024, and Q4 2021 respectively.